News Archive 2006
Clues to how diet might affect the immune system
02 Dec 2006
Garvan scientists are proposing that dietary fats can affect how well our immune system works and have discovered that one of the earliest steps in immune system activation relies on a molecule that binds fats.
New prostate cancer marker helps identify men whose cancer is likely to spread
05 Oct 2006
Prostate cancer researchers at Sydney’s Garvan Institute found a new marker for identifying aggressive prostate cancers.
New prostate cancer marker helps identify men whose cancer is likely to spread
MEDIA RELEASE:
04 Oct 2006
Garvan’s Peter Wills Bioinformatics Centre receives $1.13 million
04 Oct 2006
Garvan’s Peter Wills Centre for Bioinformatics, which models and predicts diseases by applying information science to biology, received $1.13 million from a fundraising evening held by CRI in late September.
Traditional Chinese medicine for diabetes has scientific backing
MEDIA RELEASE:
01 Aug 2006
Reports of a traditional Chinese medicine having beneficial effects for people suffering from type 2 diabetes now has some scientific evidence to back up the claims. A collaboration between Chinese, Korean, and Australian scientists at Sydney’s Garvan Institute, has revealed that the natural plant product berberine could
be a valuable new treatment.
Traditional Chinese Medicine for diabetes has scientific backing
01 Aug 2006
Reports of a traditional Chinese medicine having beneficial effects for people suffering from type 2 diabetes now has some scientific evidence to back up the claims.
Asthma - Obesity Link : protein linked to diabetes & obesity now has new role in controlling airway inflammation in asthma
MEDIA RELEASE:
15 Jul 2006
A new asthma gene provides an unexpected link between asthma and obesity according to a research team at Sydney’s Garvan Institute, who are also part of the Cooperative Research Centre for Asthma and Airways. Bennett Shum and colleagues have found that a fatty acid binding protein called aP2, which is already known for its role in diabetes and obesity, is also present in the lung where it is crucial in controlling inflammation in asthma.
Garvan student receives recognition at international conference
11 Jul 2006
Bennett Shum, PhD student in Garvan's Immunology & Inflammation Research Program, has been awarded the ICF Outstanding Scholar Award. Bennett & colleagues recently found a link between Asthma and Obesity, a fatty acid binding protein called aP2.
2005 Young Investigator of the Year
01 Jul 2006
Dr Andrew Biankin, Head of Pancreatic Cancer Research, is the recipient of the highly acclaimed 2005 Cure Cancer National Young Researcher of the Year award.
Cancer cells suppress large regions of DNA by a reversible process that can be tackled with new therapies
MEDIA RELEASE:
25 Apr 2006
Cancer researchers at Sydney’s Garvan Institute, in collaboration with Spanish scientists, have formulated a new concept for how cancer cells can escape normal growth controls, which may have far-reaching implications for the new generation of cancer therapies.
Cancer cells suppress large regions of DNA by a reversible process that can be tackled with new therapies
05 Apr 2006
Cancer researchers at Sydney’s Garvan Institute, in collaboration with Spanish scientists, have formulated a new concept for how cancer cells can escape normal growth controls, which may have far-reaching implications for the new generation of cancer therapies.
Garvan Scientists discover exclusivity of enzyme found in immune cells
31 Mar 2006
Kate Jeffrey and colleagues in Garvan's Immunology and Inflammation Program have discovered a finding which has major implications for the design of a new class of anti-inflammatory drugs.
Sydney scientists discover & license breakthrough anti-inflammatory treatment
MEDIA RELEASE:
09 Feb 2006
Scientists from the Garvan Institute of Medical Research have developed what could be the next big blockbuster treatment for inflammatory diseases such as rheumatoid arthritis and asthma. This discovery is being commercialised by G2 Therapies Ltd, a
biotechnology company founded by Garvan, which today announced the signing of an AU$135 million research, development and licensing agreement with Danish healthcare company, Novo Nordisk.
Sydney scientists discover & license breakthrough anti-inflammatory treatment
08 Feb 2006
Scientists from the Garvan Institute of Medical Research have developed what could be the next big blockbuster treatment for inflammatory diseases such as rheumatoid arthritis and asthma.
Garvan receives equipment grant from the Lupus Association of NSW
03 Feb 2006
Professor Fabienne Mackay and her team from the Arthritis and Immunology program have been awarded a $55 000 grant by the NSW Lupus Association
Garvan student wins prestigious University Medal
01 Feb 2006
Yvonne Ng, a 2005 Honours student in the Diabetes and Obesity Research Program, has won the UNSW University Medal for Molecular Biology
A FAT chance of becoming manic-depressive
10 Jan 2006
A collaboration led by Sydney scientists at the Garvan Institute of Medical Research and University of New South Wales has discovered the first risk gene specifically for bipolar disorder also known as manic-depressive illness. This means that people who have a particular form of this gene are twice as likely to develop the disease.
